Crucell Has Had Merger Talks With Wyeth

Updated from 5:43 p.m. EST

Dutch biopharmaceutical company Crucell (CRXL Quote) said Wednesday it has been involved in talks that could lead to its acquisition by Wyeth (WYE Quote).

Crucell, which is known for vaccines and infectious-disease treatments, said the discussions are at a preliminary stage, and there is no assurance that a transaction will be reached.

The Wall Street Journal, citing people who had knowledge of the situation, reported that a deal with Wyeth could value Crucell at more than $1.35 billion. The report added that another company, perhaps Novartis (NVS Quote) or Sanofi-Aventis (SNY Quote), could be interested in Crucell, as well. ...